

# A Comprehensive Evaluation of a Novel Color Range Indicator in Multiple Blood Glucose Meters Demonstrates Improved Glucose Range Interpretation and Awareness in Subjects With Type 1 and Type 2 Diabetes

Journal of Diabetes Science and Technology  
2016, Vol. 10(6) 1324–1332  
© 2016 Diabetes Technology Society  
Reprints and permissions:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/1932296816659307  
dst.sagepub.com  


Mike Grady, PhD<sup>1</sup>, Laurence B. Katz, PhD<sup>2</sup>, Hilary Cameron, BSc (Hons)<sup>1</sup>, and Brian L. Levy, MD<sup>2</sup>

## Abstract

**Aims:** We previously demonstrated that people with type 2 diabetes (T2DM) can improve their ability to categorize blood glucose (BG) results into low, in range, or high glycemic ranges after experiencing a color range indicator (CRI or ColorSure™ Technology) in a single meter. This study examined whether a CRI was effective in people with type 1 (T1) or T2DM when used in 3 glucose meters.

**Methods:** A total of 179 subjects (139 T2DM and 40 T1DM) classified BG values as low, in range, or high based on individual current knowledge. Subjects then experienced the CRI which showed whether different BG values were low, in range, or high. After CRI interaction, subjects repeated the classification.

**Results:** Following interaction with the CRI, subjects significantly improved their ability to categorize BG results into low, in range, and high glycemic ranges by 27.9% (T2DM) and 27.2% (T1DM) (each  $P < .001$ ). Improvement was not accompanied by an increase in time spent categorizing results. There was no difference in classification ability between subjects with T1 or T2DM. There was also no correlation between HbA1c, numeracy level, test frequency, or duration of diabetes and the ability to correctly classify results. Subjects agreed the CRI feature helped them easily interpret glucose values and improved their awareness of glucose ranges.

**Conclusion:** Interaction with a CRI improved the ability of subjects with T1 and T2DM to interpret and categorize BG values into recommended glycemic ranges, irrespective of the glucose meter providing the CRI insights.

## Keywords

color range indicator (ColorSure™ Technology), progress notes, glucose ranges, blood glucose monitor, self-monitoring of blood glucose, numeracy


Self-monitoring of blood glucose (SMBG) is an integral component of effective diabetes management, allowing patients to evaluate their individual response to therapy and assess whether individual glycemic targets are being achieved.<sup>1,2</sup> Appropriate education addressing SMBG interpretation and particularly the response to “out of-range” blood glucose (BG) results are prerequisites for the useful performance of SMBG.<sup>3,4</sup> Recent studies have highlighted the issue of interpreting and responding to SMBG. A study in 207 patients with T2DM<sup>5</sup> investigating perceptions of high BG results demonstrated that the subjects were more tolerant of high BG levels than is clinically advisable. In addition, a survey of 886 people with T2DM showed that about

half of insulin and non-insulin-using patients with T2DM regularly took no action for out-of-range BG values (low or high) with any self-care adjustments.<sup>6</sup> We recently reported that a blood glucose meter (BGM) that provides automatic on-screen glucose range information using a color range indicator (CRI)

<sup>1</sup>LifeScan Scotland Ltd, Inverness, UK  
<sup>2</sup>LifeScan Inc, West Chester, PA, USA

## Corresponding Author:

Mike Grady, PhD, LifeScan Scotland Ltd, Beechwood Park North, Inverness, IV2 3ED, UK.  
Email: mgrady@its.jnj.com



**Figure 1.** BGM color range indicator (CRI) and progress notes screens. (A) OneTouch Select Plus, CRI; (B) OneTouch Verio Flex, CRI; (C) OneTouch Verio, CRI; (D) OneTouch Verio, Progress Notes.

significantly improved the ability of subjects with T2DM to classify BG readings into low, in range, or high glycemic ranges.<sup>7</sup> This may support optimal diabetes self-management.

In the current study, we investigated whether a CRI tool was effective when delivered on 2 additional BGMs. In addition, since people with T1DM perform more frequent SMBG than people with T2DM and perceptions exist that they are more adept at interpreting SMBG data,<sup>8</sup> we explored the effect of a CRI on subjects with T1DM. Finally, because poor numeracy skills have been associated with suboptimal glycemic outcomes in people with both T2DM<sup>9</sup> and T1DM,<sup>10</sup> we investigated the relationship between interpreting SMBG data and numeracy.

## Subjects

The study was conducted at 3 National Health Service (NHS) clinics in the UK (Highland Diabetes Institute, Inverness; Edinburgh Royal Infirmary, Edinburgh; Birmingham Heartlands Hospital, Birmingham) and approved by the relevant ethics committees. Subjects provided written informed consent before starting the study. Subjects were aged  $\geq 16$  years, diagnosed with diabetes for at least 6 months and currently performing SMBG. Subject's most recent laboratory A1c result (within the last 6 months) was obtained from the NHS database.

## Materials and Methods

### Blood Glucose Meters

Subjects utilized PC-based computer simulations of OneTouch Select® Plus (OTSP) meter in 59 subjects with T2DM; OneTouch VerioFlex™ (OTVF) meter in 40 different subjects with T2DM; OneTouch Verio® (OTV) meter in 80 different subjects, 40 T2DM and 40 T1DM. All 3 meters are marketed by LifeScan Inc (Wayne, PA).

### CRI Feature

Subjects experienced the CRI feature (ColorSure™ Technology) using interactive computer simulators that mirrored the displays of the respective glucose meters. The CRI tool automatically indicates whether the BG result displayed on the screen is “low” (below range), “in range,” or “high” (above range). The CRI on OTSP uses a note that points to a blue, green or red bar on the meter casing and displays the text “low,” “in range,” or “high” (Figure 1A). OTVF uses a simple arrow (without text) to indicate the glucose range (Figure 1B). In OTV, a CRI color dot appears alongside text on each results screen to indicate the glucose range (Figure 1C). The message depends on the glucose range set in the meter by the patient or health care professional (HCP). Low ( $<70$  mg/dl), in range (70-180 mg/dl), and high ( $>180$  mg/dl) default limits are provided preset in the meter and were used in this study.

### Progress Notes Feature

In addition to the CRI, OTV displays progress notes that automatically describe how many BG results are in range over the last 7 days (Figure 1D).<sup>11</sup> The algorithm displays a progress note when  $\geq 70\%$  of results are within the customizable range limit. The value of this feature to patients was explored via logbook comparisons and subject surveys.

## Study Design

### Glucose Readings Classification

#### Step 1

Subjects classified 50 glucose readings as low, in range, or high based on their current knowledge.

### Step 2

Subjects interacted digitally with BGM simulators to experience how the CRI tool classified a different set of 30 glucose readings. Subjects used a mouse to click on the test strip picture on the screen to visually insert a strip into the meter and then clicked on the test strip edge to simulate a 5 second blood glucose test. After 5 seconds, a pre-programmed glucose reading with the appropriate CRI low, in range, or high message (note, arrow, or dot) was displayed. Subjects repeated this process at their own pace to simulate 30 home glucose tests. Subjects then interactively scrolled through these results either using the results log history (OTSP and OTVF) or simply reviewed the results screens (OTV) showing how each BGM categorized the results.

### Step 3

Subjects repeated the original exercise in step 1 to classify the original 50 glucose readings.

The study facilitator recorded the time it took subjects to complete each step. The default glycemic ranges were not disclosed to subjects during any of these steps.

**Progress Notes Feature.** After the CRI exercises, 169 subjects (40 T1DM; 129 T2DM) reviewed BG results on a paper logbook in which 7 of 10 logbook results were in range. At this time the facilitator explained that in range meant 70-180 mg/dl and this range was also written on the logbook itself. Each subject was asked to review identical logbooks and determine how many logbook results were in range in the last 7 days. Each subject was then shown the progress notes screen in OTV and asked to confirm how many results were in range in the last 7 days.

**Subjective Numeracy Scale (SNS) Evaluation.** In all, 40 T1DM and 129 T2DM subjects took part in a subjective numeracy assessment using the Subjective Numeracy Scale (SNS), which comprised 8 numeracy statements with 6 potential responses for each statement that most represented themselves.<sup>12</sup> A total numeracy score was determined for each subject.

**Subject Surveys.** After all study procedures were completed, subjects completed surveys to investigate their knowledge of glucose ranges and explore how subjects interpret and might respond to low or high glucose readings. Finally, subjects expressed their perception of the value of the CRI tool and progress notes features with respect to managing their diabetes.

### Statistical Analyses

Continuous demographic variables were described as median and range or mean and standard deviation (SD). Categorical

demographic variables were described as percentages within categories. Test score changes were calculated as the percentage change from baseline. The null hypothesis " $H_0$ : Pretraining score = posttraining score" was tested using a paired *t*-test with a significance level  $\alpha = .05$ . Correlations with A1c and other variables were assessed using the Pearson correlation coefficient and were deemed significant at  $P < .05$ . Minitab 16.1.1 and SPSS 21.0 were used for all analyses.

## Results

### Subjects

Baseline characteristics of the 139 T2DM and 40 T1DM subjects are shown in Table 1. There was no statistically significant difference in baseline characteristics across the 3 meter groups in the T2DM subjects (data not shown).

### Glucose Readings Classification

On average, subjects correctly classified 37.3 of the 50 readings in Step 1 into their appropriate ranges (39.8 T1DM; 36.6 T2DM). After exposure to the CRI tool, the average correct number of responses increased to 46.1 of 50 (48.4 T1DM; 45.5 T2DM), representing a statistically significant improvement against baseline ( $P < .001$ ) of  $27.7\% \pm 2.2\%$  (SEM) ( $27.2\% \pm 5.2\%$  T1DM;  $27.9\% \pm 2.5\%$  T2DM). The individual subject improvement (or decline) in score is shown in Figure 2. Subjects took a mean of 2.2 min (1.7 min T1DM; 2.4 min T2DM) to classify all 50 general readings during step 1, and 1.9 min (1.5 min T1DM; 2.0 min T2DM) after CRI interaction. The difference in time spent during these steps was not statistically significant. The average time spent interacting with the CRI tool itself (during Step 2) was less than 6 min, with a range of 1 to 14 min.

### Range Classification and Clinical Measures

Subject baseline A1c ranged between 5.0% to 14.2%. There was no correlation between A1c and the ability of subjects with T1 or T2DM to classify 50 glucose readings into appropriate glucose ranges. There was also no correlation between baseline SMBG frequency or duration of diabetes and the ability of subjects to correctly classify glucose readings.

### SNS Evaluation

Median numeracy score was 30 (maximum score of 48) across all subjects with a range of 8 to 45 (9-43 T1DM; 8-45 T2DM) (Figure 3). There was no statistical difference between numeracy scores in subjects with T1 or T2DM. In addition, there was no correlation between numeracy score and the ability to classify BG results into acceptable ranges.

**Table 1.** Baseline Patient Demographics and Medical History.

	All subjects (N = 179)	T2DM (n = 139)	T1DM (n = 40)
Male (n, %)	96 (53.6%)	76 (54.7%)	20 (50.0%)
Female (n, %)	83 (46.4%)	63 (45.3%)	20 (50.0%)
Age (years)			
Mean (SD)	55.2 (14.8)	60.0 (14.9)	38.7 (10.9)
Median (range)	58.1 (16.2-81.1)	59.7 (20.8-81.1)	39.7 (16.2-68.8)
Years conducting SMBG			
Mean (SD)	12.6 (8.1)	11.5 (9.4)	16.2 (7.4)
Median (range)	11.1 (0.8-35.1)	9.9 (0.8-31.9)	15.6 (1.1-35.1)
Frequency of SMBG (n, %)			
>6 times	4 ( 2.2%)	0	4 (10.0%)
5-6 times/day	14 ( 7.9%)	7 (5.1%)	7 (17.5%)
4 times/day	42 (23.5%)	27 (19.4%)	15 (37.5%)
3 times/day	26 (14.5%)	24 (17.3%)	2 (5.0%)
2 times/day	37 (20.7%)	32 (23.0%)	5 (12.5%)
1 time/day	18 (10.1%)	14 (10.1%)	4 (10.0%)
<1 time/day	38 (21.2%)	35 (25.2%)	3 (7.5%)
Therapy (n, %)			
Insulin pump	2 (1.1%)	0	2 (5.0%)
Insulin injections	68 (38.1%)	30 (21.6%)	38 (95.0%)
Insulin injections and OADs	71 (39.7%)	71 (51.1%)	0
OADs only	38 (21.2%)	38 (27.2%)	0
HbA1c (%)			
Mean (SD)	8.5 (1.7)	8.5 (1.8)	8.7 (1.7)
Median (range)	8.2 (5.0-14.2)	8.2 (5.0-13.9)	8.5 (5.1-14.2)

### Progress Notes Feature

After reviewing a paper logbook, only 42% of 169 subjects correctly identified that 7 of 10 weekly logbook results were in range (53% T1DM; 39% T2DM) despite being told the range. T1DM subjects were no better at correctly identifying in-range results using a paper logbook than T2DM subjects ( $P = .16$ ). However, 94% of all subjects correctly confirmed that the OTV progress notes screen described that 7 of 10 weekly BG results were in range with no statistical difference between T1DM or T2DM subjects (Figure 4).


### Subject Surveys

**Subject Awareness on Glucose Ranges.** Of subjects, 76% (98% T1DM; 70% T2DM) confirmed they had previously discussed glucose ranges with their HCP. In all, 43% responded that their HCP mentioned glucose ranges at every scheduled visit (54% T1DM; 39% T2DM), and 25% said that their HCP mentioned it only sometimes (33% T1DM; 22% T2DM). Furthermore, 32% of subjects (55% T1DM; 26% T2DM) stated their HCP had previously given verbal and written glucose ranges, while 40% of all subjects reported that they only received verbal information.

**Subjects Perceptions of High or Low Glucose Readings.** When subjects were asked “Is there a low glucose value you would prefer

to stay above during routine SMBG?,” 94% specified a low limit (95% T1DM; 94% T2DM). Of these subjects, 98% said they would prefer to be above 70 mg/dl with 45% preferring to always be above 90 mg/dl (26% T1DM; 50% T2DM). When asked, “Is there a high glucose value you would prefer to stay below during routine SMBG?,” only 37% said they would prefer to stay below 180 mg/dl (32% T1DM; 38% T2DM), with the remaining preferring to stay below higher target limits (68% T1DM; 62% T2DM). When subjects were asked, “Is there a low glucose reading at which you would take action (to raise blood glucose)?,” 99% responded they would act below 70 mg/dl. When subjects were asked the same question for high readings, 72% said they would only act above 180 mg/dl (98% T1DM; 65% T2DM), and 28% said they would not take action at any high glucose reading (2% T1DM; 35% T2DM).

**Subject Perceptions of the CRI and Progress Notes Tool.** Table 2 shows the responses of subjects to statements regarding OTSP, OTVF, OTV, and the progress notes feature of OTV. Of subjects in the OTSP group, 96% agreed the CRI made them more aware of their target ranges and could help them quickly (92%) and easily (90%) interpret their BG readings. Of subjects in the OTVF group, 98% agreed that the simple CRI helped them know where they stand and could help them quickly (95%) and easily (95%) understand their BG readings. Of subjects in the OTV group, 90% agreed that seeing a positive progress note would boost their confidence and




**Figure 2.** Change in glucose result classification scores. Each bar represents an individual subject.

help them feel reassured about the actions they had been taking to manage their diabetes.


## Discussion

Despite it being generally accepted that patients find health-related data such as BG monitoring results difficult to understand,<sup>13</sup> studies evaluating how well patients are

able to comprehend information (including SMBG data) or how this information directly affects outcomes is not well reported.<sup>14</sup> The baseline data in our study reinforce the idea that some patients struggle with basic interpretation of glucose data. In addition, one cannot assume that patients who test their blood sugars more frequently, such as patients with T1DM or insulin-using patients with T2DM, are more capable of interpreting glucose results due to



**Figure 3.** Subjective Numeracy Scale scores in T1DM (n = 40) and T2DM (n = 129) subjects. The 8-question scale has 6 items per question, with a maximum score of 48 representing highest subjective numeracy evaluation. Numbers represent the number of subjects scoring in the range shown.



**Figure 4.** Success determining number of in-range results after reviewing a paper logbook or viewing a BGM progress note. Scores are percentage success rate correctly identifying that 7 of 10 BG results were in range (3.9-10.0 mmol/l).

their supposed familiarity with glucose results. Consistent with this idea, although subjects in our study with T1DM had a slightly higher baseline ability to classify BG results into appropriate ranges compared with T2DM subjects, this difference was not significant.

Recent evidence has shed light on how patients with T1DM perceive information on glucose ranges and targets. Rankin et al<sup>15</sup> explored experiences of implementing BG targets in 30 patients in the UK with T1DM and found use of BG targets enabled patients to more easily identify problems.

**Table 2.** Subject Responses to Survey Statements.

OT Select Plus (n = 59, T2DM)	Favorable responses (%)
The meter with its range indicator makes me more aware of my target range	96.0
The meter with its range indicator helps me quickly interpret my blood glucose readings	92.0
The meter with its range indicator helps me easily interpret my blood glucose readings	90.0
<b>OT Verio Flex (n = 40, T2DM)</b>	
The meter with simple color range indicator could help me recognize what I am doing right	97.5
Each time I test, the meter with simple color range indicator provides a clear understanding of my blood sugar reading	97.5
The simple color range indicator gives me readings so clear, that it could help me know where I stand	97.5
<b>OT Verio (n = 80, 40 T1DM, 40 T2DM)</b>	
The large, clear numbers, 3 color range indicator feature and progress notes could help simplify the way I manage my diabetes	85.0
The 3 color range indicator on this meter would help encourage me to stay on track	80.0
This meter with color range indicator feature would help make it clearer when I need to take action compared to a meter without CRI	80.0
<b>Progress Notes (n = 169, 40 T1DM, 129 T2DM)</b>	
Seeing a positive progress note would boost my confidence about how well I am managing my diabetes	91.1
A positive progress message would help me feel reassured about the actions I have been taking to manage my diabetes	89.9
By showing me when I am in range, the progress notes on this meter could encourage me to stay on track	89.3

Favorable responses are defined as a response of "strongly agree" or "agree" on a 5-point scale (5 = strongly agree, 4 = agree, 3 = neither agree nor disagree, 2 = disagree, and 1 = strongly disagree). All favorable response rates are statistically significant ( $P < .05$ ).

Therefore, a simple color range indicator, personalized to the appropriate BG target range by an HCP, may help T1DM patients recall BG targets and enable them to more confidently refine their range limits over time and improve glyce-mic control.

Our study demonstrated that providing automatic on-screen glucose range advice via a color range indicator significantly improved the ability of subjects to classify BG readings into low, in range, or high ranges. Improved ability to interpret and classify BG readings was consistent across 3 different glucose meters regardless of how each meter displayed the advice. Furthermore, these improvements were of equal magnitude in subjects with T2DM and T1DM.

Our subject survey noted that although nearly all subjects with T1DM discuss glucose ranges at their scheduled HCP visits, only 70% of subjects with T2DM did so even though many of them were insulin users. This tendency to a stronger focus on glycemic targets during encounters of people with T1DM with their HCP is understandable given the need to avoid hypoglycemia when dosing insulin. But it does seem an area of opportunity for people with T2DM to be provided with more consistent feedback from their HCP regarding glucose ranges. Again, the simplicity of displaying range targets on a meter using a color range indicator may be helpful. Interestingly, there is an apparent disconnect between perceptions of HCPs and people with T2DM with respect to diabetes management advice received in routine clinical practice. An observational study surveying 1,012 T2DM patients and 974 physicians found that almost half of physicians thought they

assessed treatment adherence "very often," while only 17% of patients agreed with this statement.<sup>16</sup> And while most physicians (63%) felt treatment adherence was "very important" to achieve optimal clinical outcomes, only 25% of the patients with T2DM considered this attribute of great importance to their physician. Therefore, the ability to customize patient BGMs with personalized glucose target ranges may facilitate patient adherence by providing repeated reminders of HCP-advised treatment goals between scheduled visits.

We also examined the perceptions of our study population to BG values, both in terms of ranges they would routinely prefer to be within and with respect to actions they would be inclined to take when results were low or high. Survey results highlighted similarities and differences between subjects with T1DM and T2DM. Nearly all subjects in our study preferred their BG results to be above 70 mg/dl and would take some form of action below this threshold. However, it was interesting to note that subjects with T2DM had a more variable response to acceptable low glucose targets, with 50% of them preferring to stay above 90 mg/dl most of the time, double the percentage stated by T1DM subjects. Similar percentages of T1 and T2DM subjects preferred to keep their high results below 180 mg/dl, but in contrast to T1DM subjects where nearly all would take some form of action above 180 mg/dl, only 24% of subjects with T2DM considered action when above 250 mg/dl and 35% stated they would take no action of any kind for any high glucose. This apparent tolerance of high results by subjects with T2DM may reflect a genuine lack of range awareness. The CRI feature may help identify high results and prompt patients to reflect

on the advice of their HCPs in regard to responding to high glucose readings.

Recently, Zikmund-Fisher et al<sup>17</sup> reported that numeracy and literacy independently predict the ability of patients to identify out-of-range test results. In addition, poor numeracy skills have been associated with worse glycemic control in patients with T1DM.<sup>10</sup> In our study, we observed that both low and high numeracy subjects improved their ability to classify BG results after exposure to CRI, further demonstrating the potential benefit of CRI.

Utilizing written logbooks for recording BG data is problematic due to a high incidence of errors, information gaps, and the complexity and volume of information presented.<sup>18</sup> Approximately half of adult SMBG logbooks are considered inaccurate and unreliable.<sup>19</sup> Given that many patients become overwhelmed and unable to interpret or act upon logbook data, we investigated whether a meter-based progress notes tool, automatically displaying the number of in-range results over the last 7 days, would help patients interpret in-range results. Our data demonstrated that this tool improved the ability of subjects with both T1DM and T2DM to correctly identify how many results were in range. Perhaps not surprisingly, our data suggest that subjects with T1DM who perform SMBG more frequently are more successful in determining results in range from a paper logbook than their T2DM counterparts. Progress notes are designed to be a positive message to motivate patients to continue positive behaviors and reflect on recent actions and therapy adjustments. Our survey showed that over 90% of subjects agreed progress notes would boost their confidence and help them feel reassured about the actions they are taking to manage their diabetes.

## Summary and Conclusions

Many people with T2DM struggle to interpret BG data with respect to accepted glycemic target ranges. The current study strengthens this view and suggests that patients with T1DM have similar issues and may derive similar benefit from exposure to a CRI tool. Using meters that simplify the comprehension and interpretation of glucose data may support patients making more informed decisions and help them to follow HCP recommendations on glycemic targets.

## Abbreviations

A1c, hemoglobin A1c; BG, blood glucose; BGM, blood glucose meter; CRI, color range indicator; HCP, health care professional; NHS, National Health Service; OAD, oral antidiabetes drug; OTSP, OneTouch Select Plus; OTV, OneTouch Verio; OTVF, OneTouch VerioFlex; SD, standard deviation; SEM, standard error of the mean; SMBG, self-monitoring of blood glucose; SNS, Subjective Numeracy Scale.

## Acknowledgments

The authors would like to thank Barry Irvine, Nichola Purvis, Krisna Korla, and Lorna Stewart for support of the study conduct.

The authors received editorial assistance from Excerpta, which was funded by LifeScan, Inc.

## Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MG and HC are employees of LifeScan Scotland, Ltd. LBK and BLL are employees of LifeScan, Inc.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by LifeScan, Inc.

## References

- Standards of medical care in diabetes. Glycemic targets. *Diabetes Care*. 2016;39(suppl 1):S39-S47.
- AACE/ACE consensus statement on the comprehensive type 2 diabetes management algorithm. *Endocr Pract*. 2016;22(1):84-113.
- Moreland EC, Volkening LK, Laffel LM. Use of a BGM manual to enhance monitoring adherence in adults with diabetes. *Arch Intern Med*. 2006;166(6):689-695.
- Clar C, Barnard K, Cummins E. Self-monitoring of blood glucose in type 2 diabetes: systematic review. *Health Technol Assess*. 2010;14(12),.
- Evans JMM, Mackison D, Vivien Swanson V. Self-monitoring of blood glucose in type 2 diabetes: patients' perceptions of "high" readings. *Diabetes Res Clin Pract*. 2013;102:e5-e7. <http://dx.doi.org/10.1016/j.diabres.2013.07.011>.
- Polonsky WH, Fisher L, Hessler D, Edelman SV. A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed? *Curr Med Res Opin*. 2011;27(S3):31-37.
- Grady M, Warren G, Levy BL, Katz LB. Interactive exposure with a blood glucose monitor with a novel glucose color range indicator is associated with improved glucose range interpretation and awareness in patients with type 2 diabetes. *J Diabetes Sci Technol*. 2015;9(4):841-848.
- Miller KM, Beck RW, Bergenstal RM. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. *Diabetes Care*. 2013;36:2009-2014.
- Teft G. The role of numeracy in diabetes care. *J Dia Nurs*. 2011;15(7):268-273.
- Marden S, Thomas PW, Sheppard ZA. Poor numeracy skills are associated with glycaemic control in type 1 diabetes. *Diabet Med*. 2012(29):662-669.
- Katz LB, Stewart LS, Levy BL. Benefits to health care professionals and patients with diabetes of a novel blood glucose meter that provides pattern recognition and real-time automatic messaging compared to conventional paper logbooks. *Int Diabetes Nurs*. 2015;12:27-33.
- Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. *Med Decision Making*. 2007;27:672-680.
- Cefula WT. Right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for non-insulin users. *Diabetes Care*. 2013;36:179-182.



14. Polonsky WH, Fisher L. When does personalized feedback make a difference? A narrative review of recent findings and their implications for promoting better diabetes self-care. *Curr Diabetes Rep.* 2015;15:50.
15. Rankin D, Cook DD, Heller S. Experiences of using blood glucose targets when following an intensive insulin regimen: a qualitative longitudinal investigation involving patients with type 1 diabetes. *Diabet Med.* 2012;29:1079-1084.
16. Franch-Nadal J, Barba EL, Gomez-Garcia MC. Patient-reported outcomes in type 2 diabetes mellitus: patients' and primary care physicians' perspectives in the Spanish health care system. *Patient Prefer Adherence.* 2015;9:1413-1422.
17. Zikmund-Fisher BJ, Exe NL, Witteman HO. Numeracy and literacy independently predict patients' ability to identify out-of-range test results. *J Med Internet Res.* 2014;16(8):e187.
18. Hirsch IB. Blood glucose monitoring technology: translating data into practice. *Endocr Pract.* 2004;10:67-76.
19. Given JE, O'Kane MJ, Bunting BP, Coates VE. Comparing patient-generated blood glucose diary records with meter memory in diabetes: a systematic review. *Diabet Med.* 2013;30:901-913.